Главная › Рак яичников › Колорадо › Aurora
Клинические исследования Рак яичников в городе Aurora, CO
25 исследований по теме Рак яичников ищут участников в центрах в городе Aurora и поблизости (в радиусе около 30 миль). Откройте исследование, чтобы узнать критерии участия и контакты исследовательской группы.
Официальный текст исследования (на английском)
Ищете участников для исследования? Разместите его вверху страницы — $99 на 30 дней →
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
Набор участниковФаза 2/3
- UCHealth University of Colorado Hospital, Aurora
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Набор участниковФаза 2
- UCHealth University of Colorado Hospital, Aurora
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Набор участниковФаза 1/2
- Research Site, Aurora
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
Набор участниковФаза 2
- University of Colorado Hospital- Aurora /ID# 278232, Aurora
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
Набор участниковФаза 1/2
- University of Colorado Denver, Aurora
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Набор участниковФаза 3
- Anschutz Cancer Pavilion, Aurora
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Набор участниковФаза 1/2
- University of Colorado Cancer Center, Aurora
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Набор участниковФаза 1
- University of Colorado Cancer Center, Aurora
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Набор участниковФаза 3
- University of Colorado Cancer Center, Aurora
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Набор участниковНаблюдательное исследование
- University of Colorado, Aurora
Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence
Набор участниковФаза 1
- Outpatient CTRC, Aurora
- University of Colorado Cancer Center, Aurora
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Набор участниковФаза 1/2
- Children's Hospital Colorado, Aurora
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Набор участников
- UCHealth University of Colorado Hospital, Aurora
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Набор участниковФаза 3
- UCHealth University of Colorado Hospital, Aurora
Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer
Набор участниковФаза 1
- CU Medicine Clinics, Aurora
- Universtiy of Colorado Hospital, Aurora
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
Набор участниковФаза 2
- University of Colorado Hospital, Aurora
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Набор участниковФаза 1/2
- University of Colorado Cancer Center, Aurora
The EASE Study: Randomized Trial of a Novel Approach to Addressing Fear of Progression in Advanced Cancer
Набор участников
- University of Colorado Anschutz Medical Campus, Aurora
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
Набор участниковФаза 1/2
- University of Colorado, Anschutz Medical Campus, Aurora
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Набор участниковФаза 3
- University of Colorado Hospital - Anshutz Cancer Pavilion, Aurora
REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors
Набор участников
- University of Colorado Cancer Center-Anschutz, Aurora
A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
Набор участниковФаза 1
- Site 0264, Aurora
Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis
Набор участниковФаза 1
- University of Colorado Cancer Center, Aurora
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Набор участниковНаблюдательное исследование
- Massive Bio SYNERGY-AI site, Aurora
Gonadal Dysgenesis Tissue Cryopreservation for Fertility Preservation
Набор участников
- University of Colorado, Aurora
Исследования Рак яичников в других городах
- Houston, TX89 исследований
- New York City, NY69 исследований
- Boston, MA61 исследование
- Los Angeles, CA50 исследований
- Nashville, TN49 исследований
- Arlington, VA46 исследований
- Philadelphia, PA44 исследований
- Columbus, OH39 исследований
- St. Louis, MO38 исследований
- Chicago, IL36 исследований
- San Antonio, TX31 исследование
- Cleveland, OH30 исследований
Другие исследования в городе Aurora
- Рак (все виды)35 исследований
- Колоректальный рак32 исследований
- Немелкоклеточный рак легкого31 исследование
- Рак молочной железы28 исследований
- Метастатический рак25 исследований
- Сахарный диабет 1 типа23 исследований
- Ожирение22 исследований
- Рак простаты19 исследований
- Рак легких19 исследований
- Сердечная недостаточность18 исследований
- Меланома18 исследований
- Острый миелоидный лейкоз16 исследований
Источник: ClinicalTrials.gov, данные получены 6 окт. 2026 г.. Каждая исследование устанавливает свои критерии участия; решение о включении принимает исследовательская группа.